FARALLON CAPITAL PARTNERS LP 13D and 13G filings for Agios Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-04 12:02 pm Purchase |
2024-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
FARALLON CAPITAL PARTNERS LP | 5,674,466 9.900% |
13,600 (+0.24%) |
Filing |
| 2024-11-08 2:40 pm Purchase |
2024-09-30 | 13G | Agios Pharmaceuticals, Inc. AGIO |
FARALLON CAPITAL PARTNERS LP | 5,660,866 9.900% |
1,493,264 (+35.83%) |
Filing |
| 2024-02-08 11:39 am Purchase |
2023-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
FARALLON CAPITAL PARTNERS LP | 4,167,602 7.500% |
206,000 (+5.20%) |
Filing |
| 2023-11-09 5:18 pm Purchase |
2023-10-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
FARALLON CAPITAL PARTNERS LP | 3,961,602 7.100% |
3,961,602 (New Position) |
Filing |